Aurobindo’s Latest Launches Include Truvada And Atripla Rivals
As Company Plans To Broaden Its Injectables Generics Portfolio In China
Aurobindo has announced the launch of generic versions of Truvada, Atripla, Minocin and Gleevec in the US. As its generics business grows in the US, Europe, Canada and the rest of the world markets, Aurobindo plans to establish itself in China. The Indian pharma company has also announced its plan to commission new facilities to serve the external market.
